Psychosis – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Psychosis Market Outlook

Thelansis’s “Psychosis Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Psychosis treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Psychosis Overview

Psychosis is a mental disorder characterized by a disconnect from reality, evident through a decline in daily functioning and a breakdown of personality manifested as disturbances in emotions, thoughts (like delusions), perceptions (such as hallucinations), and behavior. The primary symptoms of psychosis include:

• Hallucinations: These involve perceiving things that aren't present, such as hearing, seeing, or even feeling, smelling, or tasting things that have no physical existence. Hearing voices is a common form of hallucination.
• Delusions: These are false beliefs that, upon rational examination, are untrue. Sometimes, the cause of psychosis can be linked to specific mental health disorders, including:
• Schizophrenia leads to various psychological symptoms, including hallucinations and delusions.
• Bipolar disorder: A condition affecting mood, characterized by alternating episodes of depression (lows) and mania (highs).
• Severe depression: In some cases, severe depression can also trigger symptoms of psychosis.

Additionally, trauma, stress, physical ailments like Parkinson's disease or brain tumors, as well as substance abuse (drugs or alcohol) can all act as triggers for psychosis. Nonetheless, a combination of genetic, biological, environmental, and psychological elements is believed to play a role. Managing psychosis involves a combination of approaches, including:

1. Antipsychotic medication: These drugs help alleviate the symptoms of psychosis.
2. Psychological therapies: Cognitive Behavioral Therapy (CBT), a one-on-one talking therapy, has shown effectiveness in assisting individuals with schizophrenia. Family therapy, where applicable, has been found to reduce the necessity for hospitalization in people with psychosis.
3. Social support: Addressing social needs like education, employment, and housing.

Individuals with a history of psychosis are more likely to struggle with substance abuse issues or alcohol misuse.

• Around 3% of the population in the United States will experience at least one episode of psychosis during their lifetime. Annually, around 100,000 teenagers and young adults in the United States will encounter their inaugural episode of psychosis.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2022-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: